Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good day, and welcome to the ARS Pharmaceuticals Third Quarter ...

Ars Pharmaceuticals, Inc. ( (SPRY)) has released its Q3 earnings. Here is a breakdown of the information Ars Pharmaceuticals, Inc. presented to its investors. ARS Pharmaceuticals, Inc., a ...

Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product ...

Despite a net loss, ARS Pharmaceuticals Inc (SPRY) is optimistic about NEPHI's market potential and strategic global expansion.

ARS Pharmaceuticals (SPRY) announced a licensing agreement with ALK-Abello A/S (AKBLF), that provides ALK exclusive rights to ...

ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak ...

In a report released on November 11, Roanna Ruiz from Leerink Partners maintained a Buy rating on ARS Pharmaceuticals (SPRY – Research Report). The company’s shares closed yesterday at $16.61.

Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive ...

Cantor Fitzgerald has recently initiated ARS Pharmaceuticals Inc (SPRY) stock to Overweight rating, as announced on August 20, 2024, according to Finviz. Earlier, on August 13, 2024, Raymond James had ...

Although ARS Pharmaceuticals’ approval for its epinephrine nasal spray came later than expected, the company ultimately received a thumbs up from the FDA in August and is now moving fast to expand ...

ALK licenses rights to adrenaline nasal spray, neffy from ARS Pharma for emergency treatment of allergic reactions: Hørsholm, Denmark Tuesday, November 12, 2024, 12:00 Hrs [IST] ...